摘要:
The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1 (7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1 (7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1 (7-37); wherein the first K residue is designated K 27 , and the second K residue is designated K T ; which derivative comprises two albumin binding moieties attached to K 27 and K T , respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC-(CH 2 ) x -CO- and HOOC-C 6 H 4 -O-(CH 2 ) y -CO-; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula -NH-(CH 2 ) 2 -(O-(CH 2 ) 2 ) k -O-(CH 2 ) n -CO-, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel GLP-1 analogues. The derivatives are suitable for oral administration.
摘要:
The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates to a pharmaceutical composition comprising such a fusion protein, in particular for blocking apoptosis in a patient in need thereof. The invention also provides a polynucleotide encoding such a fusion protein, an expression vector comprising the polynucleotide and a host cell comprising the expression vector. In a further aspect, the invention relates to the use of any of theses materials for the preparation of a medicament for blocking apoptosis in a patient in need thereof.
摘要:
A recombinant virus that is more potent as an antimycoplasma vaccine is provided by preparing a DNA encoding a fused protein comprising a polypeptide having the antigenicity of Mycoplasma gallisepticum and a polypeptide derived from the outer membrane protein of a herpesvirus, wherein the latter polypeptide is connected to the N-terminal side of the former polypeptide, and integrating the prepared DNA into a region non essential for the proliferation of avipoxviruses to prepare a recombinant avipoxvirus.
摘要:
The present invention is directed to an animal model for predicting the course of orthopox virus infections or for evaluating the efficacy of anti-viral therapeutics or anti-orthopox virus vaccines. The present invention is further directed to a method of evaluating the efficacy of an anti-viral therapeutic or an anti-orthopox virus vaccine and to a specific Callithrixpox virus strain for use in this method. Furthermore, the present invention pertains to a pharmaceutical composition containing such an anti-viral therapeutic or an anti-orthopox virus vaccine.
摘要:
The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate useful cellular responses and/or antagonize undesired biological activities. Disclosed are methods which stimulate or inhibit these biological activities, methods for therapeutic applications and antagonists of ORFV2-VEGF and/or NZ10.
摘要:
The invention relates to a recombinant fowlpox virus (FWPV) and a DNA vector containing gene sequences for one such recombinant fowlpox virus. The invention also relates to a pharmaceutical composition containing said recombinant fowlpox virus or a DNA vector, to the use of said recombinant fowlpox virus for treating infectious diseases or tumour diseases, and to a method for producing said recombinant fowlpox virus or DNA vector. The invention further relates to eukaryote cells or prokaryote cells containing the recombinant DNA vector or the recombinant fowlpox virus. The invention is based on the identification of the FWPV-F11L gene as a novel insertion site for foreign DNA.
摘要:
Plants are disclosed which are capable of expressing, in a tissue or tissues susceptible to damage by feeding insects, an exogenous protein(s) such as fusolin or a fusolin-like protein, to reduce damage to the plant by inhibiting feeding, growth and/or development of insects. Feed baits comprising spindle bodies, spindle-like bodies or constituent protein(s) thereof which inhibit feeding, growth and/or development of insects are also disclosed.
摘要:
The present invention provides genes of the viral genus leporipox that encode immunomodulatory proteins. The present invention also provides therapeutic compositions containing these polypeptides and methods for use for treating a variety of inflammatory and autoimmune disorders. In one preferred embodiment, the present invention provides methods for producing the immunomodulatory polypeptides in a substantially pure form. In another preferred embodiment, the invention provides methods for treating individuals diagnosed with autoimmune or inflammatory disorders by gene therapy. In yet another preferred embodiment, the methods and compositions of the present invention may be used to treat cancer. Finally, the invention provides methods to identify and isolate additional leporipox virus immunomodulatory polypeptides.